Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]
Discontinued
Reference number: GID-TA10105
This appraisal has now been suspended and the appraisal committee discussion that was due to take place has been cancelled.
This is due to an update on the regulatory status as the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, “recommending the refusal of the marketing authorisation for the medicinal product anamorelin intended for the treatment of anorexia, cachexia or unintended weight loss in patients with non-small cell lung cancer”.